Literature DB >> 18498216

Human embryonic stem cells may display higher resistance to genotoxic stress as compared to primary explanted somatic cells.

Kumar Jayaseelan Vinoth1, Boon Chin Heng, Anuradha Poonepalli, Birendranath Banerjee, Lakshmidevi Balakrishnan, Kai Lu, M Prakash Hande, Tong Cao.   

Abstract

The use of human embryonic stem (hES) cells in genotoxicity screening can potentially overcome the deficiencies associated with using immortalized cell lines, primary explanted somatic cells, and live animal models. Hence this study sought to compare the responses of hES cells and primary explanted somatic cells (IMR-90 cells, human fetal lung fibroblasts) to genotoxic stress, to evaluate whether hES cells can accurately reflect the normal physiology of human somatic cells. The effects of mitomycin C (MMC) on the chromosomal stability of hESC and IMR-90 was assayed and compared by fluorescence in situ hybridization (FISH) with telomere-specific peptide nucleic acid and multicolor (m) FISH techniques. The results showed that, the percentage of aberrant cells increased from 6% in the untreated control to 57.5% at the higher dose of 0.06 microg/ml MMC (9.6-fold increase) group in the case of IMR-90 cells, whereas hES cells displayed a corresponding increase from 6% to 28% (4.6-fold increase). Telomere FISH ascertained that the main types of damage induced by MMC are chromosomal breaks and the loss of telomeric signals. No fusions were observed in all samples analyzed. This was further confirmed by mFISH, which showed that fusions and translocations were not the type of aberration induced by MMC, with no such aberrations being observed in all samples analyzed. Hence, hES cells of the H1 line are apparently more resistant to MMC-induced DNA damage, as compared to the IMR-90 cells. These results highlight possible intrinsic differences in response to damaging agents between hES cells and normal somatic cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18498216     DOI: 10.1089/scd.2007.0088

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  6 in total

1.  Efficient method for generating nuclear fractions from marrow stromal cells.

Authors:  Dale Woodbury; Guo-Wei Len; Kathleen Reynolds; W Geoffrey McAuliffe; Thomas Coyne; Kuo Wu
Journal:  Cytotechnology       Date:  2008-12-04       Impact factor: 2.058

2.  Heat shock induces apoptosis in human embryonic stem cells but a premature senescence phenotype in their differentiated progeny.

Authors:  Larisa L Alekseenko; Victoria I Zemelko; Valery V Zenin; Nataly A Pugovkina; Irina V Kozhukharova; Zoya V Kovaleva; Tatiana M Grinchuk; Irina I Fridlyanskaya; Nikolay N Nikolsky
Journal:  Cell Cycle       Date:  2012-08-16       Impact factor: 4.534

3.  Differentiation and enrichment of expandable chondrogenic cells from human embryonic stem cells in vitro.

Authors:  Wei Seong Toh; Xi-Min Guo; Andre B Choo; Kai Lu; Eng Hin Lee; Tong Cao
Journal:  J Cell Mol Med       Date:  2009-05-01       Impact factor: 5.310

4.  Mitomycin-treated undifferentiated embryonic stem cells as a safe and effective therapeutic strategy in a mouse model of Parkinson's disease.

Authors:  Mariana Acquarone; Thiago M de Melo; Fernanda Meireles; Jordano Brito-Moreira; Gabriel Oliveira; Sergio T Ferreira; Newton G Castro; Fernanda Tovar-Moll; Jean-Christophe Houzel; Stevens K Rehen
Journal:  Front Cell Neurosci       Date:  2015-04-08       Impact factor: 5.505

5.  Effects of Aminoglycoside Antibiotics on Human Embryonic Stem Cell Viability during Differentiation In Vitro.

Authors:  Divya S Varghese; Shama Parween; Mustafa T Ardah; Bright Starling Emerald; Suraiya A Ansari
Journal:  Stem Cells Int       Date:  2017-09-24       Impact factor: 5.443

6.  Effects of oxidative and thermal stresses on stress granule formation in human induced pluripotent stem cells.

Authors:  Freshteh Palangi; Samson M Samuel; I Richard Thompson; Chris R Triggle; Mohamed M Emara
Journal:  PLoS One       Date:  2017-07-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.